Abstract:Alport syndrome is a hereditary glomerular disease caused by mutation in the COL4A3, COL4A4, or COL4A5 gene encoding type IV collagen alpha 3, alpha 4, and alpha 5 chains (alpha 3-alpha 5(IV)), respectively, which are components of the glomerular basement membrane (GBM). The most common mutations are those in COL4A5, which comprise more than 80% of AS-associated mutations. Mutant achains cannot form alpha 345(IV) trimer, which leads to abnormal GBM. In current therapeutic approaches for the management of Alport syndrome, inhibitors of the renin angiotensin system (RAS) are typically prescribed. Although early intervention by RAS blockade suppresses the progression of nephritis, patients with Alport syndrome taking RAS inhibitor eventually develop end-stage renal disease. Numerous basic studies have revealed the molecules that are associated with the progression of Alport syndrome. However, candidate drug targets have not been assessed in clinical applications, and a novel therapeutic strategy is urgently needed. We have established collagen alpha 345(IV) heterotrimer formation assay system that is amenable to high throughput screening (HTS) by using split luciferase compliment system (NanoLucTM) (Omachi, et al., Cell Chem. Biol. 2018). The assay provided evidence that compared with wild-type alpha 345(IV) trimer, the heterotrimer with mutant alpha 5(IV) had either intracellular trimerization defect or trimer secretion defect. We have started screening of natural compounds in our original library using alpha 5(IV) G1244D-expressing cellular system, and are trying to find potential candidate compounds to correct the mutant alpha 5(IV)-dependent defect of alpha 345 (IV) trimer secretion. Furthermore, we will also discuss the recent progress on the generation of new Alport mouse models with missense mutations in C57BL/6 and 129 strains that may be usable for future analysis of the in vivo efficacy of our candidate compounds.

Adverse effects of Alport syndrome-related Gly missense mutations on collagen type IV: Insights from molecular simulations and experiments

Quantitative Analysis of Type IV Collagen Subchains in the Glomerular Basement Membrane of Patients with Alport Syndrome with Confocal Microscopy.

Pharmacological approach and diagnosis for Alport syndrome

Four novel mutations identified in the COL4A3, COL4A4 and COL4A5 genes in 10 families with Alport syndrome

Synergistic Toxicity of Compound Heterozygous Mutations in the COL4A3 Gene Causes End-Stage Renal Disease in A Large Family of Alport Syndrome

Alport syndrome and Alport kidney diseases – elucidating the disease spectrum

Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture’s and Alport diseases

[Proteins structure changes of COL4A5 gene point mutations and structure-phenotype relations in Alport syndrome].

Collagen IVα345 Dysfunction in Glomerular Basement Membrane Diseases. I. Discovery of a COL4A3 Variant in Familial Goodpasture's and Alport Diseases.

Novel Mutations In Col4a3, Col4a4, And Col4a5 In Chinese Patients With Alport Syndrome

Endoplasmic Reticulum Stress Activation in Alport Syndrome Varies Between Genotype and Cell Type

Trimerization profile of type IV collagen COL4A5 exon deletion in X-linked Alport syndrome

A Novel Missense Mutation of COL4A5 Gene Alter Collagen IV Α5 Chain to Cause X-linked Alport Syndrome in a Chinese Family.

Dissecting the genotype-phenotype correlation of <i>COL4A5</i> gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome

Alport Syndrome: a Unified Classification of Genetic Disorders of Collagen IV Alpha 345: a Position Paper of the Alport Syndrome Classification Working Group

Detection of COL4A5 Gene Mutations in Chinese Patients with Alport's Syndrome

iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome

Identification of a Novel COL4A5 Mutation in a Chinese Family with X-linked Alport Syndrome Using Exome Sequencing.

Chemical chaperones to the rescue of Alport syndrome?

A novel COL4A5 splicing mutation causes alport syndrome in a Chinese family

Three Novel Heterozygous Col4a4 Mutations Result In Three Different Collagen Type Iv Kidney Disease Phenotypes